Last reviewed · How we verify
LY4006895
At a glance
| Generic name | LY4006895 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY4006895 CI brief — competitive landscape report
- LY4006895 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI